Letter to the editor regarding 'Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: Its clinicopathological significance'

Modern Pathology

Volumn 26, Issue 4, 2013, Pages 609-610

  Chang, Martin C ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOMAL INSTABILITY; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; LETTER; ONCOGENE NEU; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84876463154     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.213     Document Type: Letter

References (6)

1. Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012;25: 938-948.
2. Bartlett AI, Starcynznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
3. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol 2009;27:2962-2969.
4. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-1998. (Pubitemid 32045895)
5. Chang MC, Malowany JI, Mazurkiewicz J, et al. 'Genetic heterogeneity' in HER2 testing by fluoresence in situ hybridization: a study of 2522 cases. Mod Pathol 2012;25:683-688.
6. Vance GH, Barry TS, Blook KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-612.